Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this trial is to determine whether it is possible to minimize radiation dose to parts of the brain that are important for thinking and learning in children who require radiation to treat their tumor, and if this will help reduce neurocognitive (thinking and learning) impairments in these patients. Patients with newly diagnosed brain or head and neck tumors who are having radiation therapy will have neurocognitive testing and MRI imaging (both research and for regular care) done as part of their participation in the study. Survivors of childhood brain tumors who completed radiation therapy at least two years before joining the study, and have not had a recurrence, will have neurocognitive testing and research MRIs completed. Healthy children will also be enrolled and have research MRIs done. The researchers will use the radiation plan to determine how much radiation was delivered to different parts of the brain. The investigators will use the MRIs to determine how the normal brain is changing after treatment; and how this compares to patients who had standard radiation treatment or who never had a brain tumor. The neurocognitive testing will be compared among different groups to see how different treatment plans affect performance on neurocognitive tests.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dzieci i młodzi dorośli w wieku od 1 do poniżej 26 lat.
- •Nowotwory zlokalizowane w mózgu lub w jego pobliżu (np. jama nosowa, zatoki przynosowe, oczodół).
- •Leczenie musi obejmować radioterapię (protonową lub fotonową).
- •Osoby, które ukończyły leczenie radioterapią mózgu co najmniej 2 lata temu i nie miały nawrotu choroby (dotyczy grupy ozdrowieńców).
- •Zdrowe dzieci do grupy kontrolnej.
✗ Disqualifies
- •Kobiety w ciąży.
- •Osoby, które nie mogą wziąć udziału w testach poznawczych (np. z powodu problemów ze zrozumieniem języka lub wcześniejszych zaburzeń neurologicznych/rozwojowych, jak zespół Downa czy autyzm).
- •Osoby, które ukończyły już radioterapię (dotyczy grupy leczonej w ramach badania).
- •Osoby z poważnymi problemami psychicznymi, neurologicznymi lub innymi chorobami (dotyczy grupy kontrolnej).
Simplified criteria — AI translation
Trial details
- Minimum age
- 1 Year
- Maximum age
- 26 Years
- Last updated (source)
- June 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Sibley Memorial Hospital
Washington D.C., United States
Johns Hopkins Hospital
Baltimore, United States
Trial contact
Sahaja Acharya, MD
Katie Lowe
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.